Advanced Enzyme Technologies Limited has informed the Exchange regarding a press release dated May 09, 2026, titled "Quarterly Earnings Release dated May 09, 2026".
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Advanced Enzyme Technologies reported strong Q4 FY26 results with revenue of ₹2,034 million, up 22% YoY. Profit after tax surged 69% to ₹453 million, while EBITDA grew 39% to ₹632 million. The company maintained zero-debt status with financial costs reduced to ₹6 million. For the full year FY26, revenue reached ₹7,458 million (+17%) and PAT hit ₹1,736 million (+30%). EBITDA margin expanded to 31% from 27% in the same quarter last year. Human Nutrition remained the largest segment at ₹1,281 million (+24%), while domestic sales now account for 52% of total revenue, up from 42% YoY. The company launched a new nutraceutical brand 'Wellfa' in India and outlined plans for strategic acquisitions while maintaining its zero-debt position.
Strong earnings beat with margin expansion signals operational efficiency improvement. The 69% PAT growth and 31% EBITDA margin indicate robust profitability, though the company faces challenges in Europe and Americas international markets. Positive for shareholders with improving return metrics.